Research programme: USP30 inhibitors - Accelero Biostructures/Mid-Atlantic BioTherapeutics
Latest Information Update: 23 Sep 2024
At a glance
- Originator Accelero Biostructures; Mid-Atlantic BioTherapeutics
- Class
- Mechanism of Action Usp30 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders; Unspecified